Skip to main navigation Skip to search Skip to main content

Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial

John Burn, Anne-Marie Axø Gerdes, Finlay Macrae, Jukka-Pekka Mecklin, Gabriela Moeslein, Sylviane Olschwang, Diane Eccles, D Gareth Evans, Eamonn R Maher, Lucio Bertario, Marie-Luise Bisgaard, Malcolm G Dunlop, Judy W C Ho, Shirley V Hodgson, Annika Lindblom, Jan Lubinski, Patrick J Morrison, Victoria Murday, Raj Ramesar, Lucy SideRodney J Scott, Huw J W Thomas, Hans F Vasen, Gail Barker, Gillian Crawford, Faye Elliott, Mohammad Movahedi, Kirsi Pylvanainen, Juul T Wijnen, Riccardo Fodde, Henry T Lynch, John C Mathers, D Timothy Bishop, CAPP2 Investigators

880 Citations (Scopus)

Abstract

Observational studies report reduced colorectal cancer in regular aspirin consumers. Randomised controlled trials have shown reduced risk of adenomas but none have employed prevention of colorectal cancer as a primary endpoint. The CAPP2 trial aimed to investigate the antineoplastic effects of aspirin and a resistant starch in carriers of Lynch syndrome, the major form of hereditary colorectal cancer; we now report long-term follow-up of participants randomly assigned to aspirin or placebo.
Original languageEnglish
JournalLancet
Volume378
Issue number9809
Pages (from-to)2081-7
Number of pages7
ISSN0140-6736
DOIs
Publication statusPublished - 2011

Keywords

  • Adenoma
  • Anti-Inflammatory Agents, Non-Steroidal
  • Aspirin
  • Chemoprevention
  • Colorectal Neoplasms, Hereditary Nonpolyposis
  • Dietary Carbohydrates
  • Double-Blind Method
  • Heterozygote
  • Humans
  • Starch

Fingerprint

Dive into the research topics of 'Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial'. Together they form a unique fingerprint.

Cite this